sutent
pfizer limited - сунитиниб - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - Антинеопластични средства - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.
lunaldin 200 micrograms sublingual tablets
200 micrograms sublingual tablets
lunaldin 100 micrograms sublingual tablets
100 micrograms sublingual tablets
lunaldin 300 micrograms sublingual tablets
300 micrograms sublingual tablets
lunaldin 400 micrograms sublingual tablets
400 micrograms sublingual tablets
lunaldin 600 micrograms sublingual tablets
600 micrograms sublingual tablets
lunaldin 800 micrograms sublingual tablets
800 micrograms sublingual tablets
runaplax 10 mg film - coated tablets
10 mg film - coated tablets
runaplax 15 mg film - coated tablets
15 mg film - coated tablets
runaplax 20 mg film - coated tablets
20 mg film - coated tablets